-
Je něco špatně v tomto záznamu ?
Age-associated prognostic and predictive biomarkers in patients with breast cancer
M. Kolečková, Z. Kolář, J. Ehrmann, G. Kořínková, R. Trojanec
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV16-31997A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
PubMed Central
od 2010
ProQuest Central
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
28599421
DOI
10.3892/ol.2017.6000
Knihovny.cz E-zdroje
- MeSH
- diagnostické techniky molekulární metody MeSH
- imunohistochemie metody MeSH
- lidé MeSH
- nádorové biomarkery chemie MeSH
- nádory prsu * epidemiologie MeSH
- prognóza MeSH
- věkové faktory * MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
To date, no comprehensive prognostic or predictive marker profiling analysis has been performed in association with the age of patients with breast cancer. In the present study, 632 breast cancer tissue samples were analyzed for expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), B-cell lymphoma (Bcl)-2 protein, HER2 gene amplification, proliferation [as evaluated by proliferating cell nuclear antigen (PCNA) and Ki-67 index], tumor grade, histological type and molecular subtype. The data revealed correlations with the age of patients. A statistically significant positive correlation was identified between patient age and expression of ER (P<0.0001). There was no significant association between patient age and PR, HER2 protein expression, HER2 gene amplification or PCNA. A significant negative correlation between age and Ki-67 expression (P<0.0001) as well as grade of tumor (P=0.007) was identified. The spectrum of molecular subtypes differed according to age (P=0.0003). The highest incidence of aggressive triple-negative and HER2-positive breast cancer was present in patients aged between 20 and 39 years. Luminal A subtype was the most frequent cancer subtype in patients from age 40 onwards, where proliferation activity declined with age and expression of hormone receptors increased along with Bcl-2 expression. Aggressive forms of breast cancer were more common in younger patients. Prognostic and predictive markers have a complex age-specific distribution. The findings of less aggressive luminal A and B subtypes in older patients, and the positive correlation with ER, PR and Bcl-2 expression reveal the potential efficacy of Bcl-2 as a marker of hormone responsiveness in these patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22008139
- 003
- CZ-PrNML
- 005
- 20230110084537.0
- 007
- ta
- 008
- 220315s2017 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/ol.2017.6000 $2 doi
- 035 __
- $a (PubMed)28599421
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kolečková, Markéta, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $d 1990- $7 xx0238146
- 245 10
- $a Age-associated prognostic and predictive biomarkers in patients with breast cancer / $c M. Kolečková, Z. Kolář, J. Ehrmann, G. Kořínková, R. Trojanec
- 520 9_
- $a To date, no comprehensive prognostic or predictive marker profiling analysis has been performed in association with the age of patients with breast cancer. In the present study, 632 breast cancer tissue samples were analyzed for expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), B-cell lymphoma (Bcl)-2 protein, HER2 gene amplification, proliferation [as evaluated by proliferating cell nuclear antigen (PCNA) and Ki-67 index], tumor grade, histological type and molecular subtype. The data revealed correlations with the age of patients. A statistically significant positive correlation was identified between patient age and expression of ER (P<0.0001). There was no significant association between patient age and PR, HER2 protein expression, HER2 gene amplification or PCNA. A significant negative correlation between age and Ki-67 expression (P<0.0001) as well as grade of tumor (P=0.007) was identified. The spectrum of molecular subtypes differed according to age (P=0.0003). The highest incidence of aggressive triple-negative and HER2-positive breast cancer was present in patients aged between 20 and 39 years. Luminal A subtype was the most frequent cancer subtype in patients from age 40 onwards, where proliferation activity declined with age and expression of hormone receptors increased along with Bcl-2 expression. Aggressive forms of breast cancer were more common in younger patients. Prognostic and predictive markers have a complex age-specific distribution. The findings of less aggressive luminal A and B subtypes in older patients, and the positive correlation with ER, PR and Bcl-2 expression reveal the potential efficacy of Bcl-2 as a marker of hormone responsiveness in these patients.
- 650 17
- $a nádory prsu $x epidemiologie $7 D001943 $2 czmesh
- 650 17
- $a věkové faktory $7 D000367 $2 czmesh
- 650 _7
- $a nádorové biomarkery $x chemie $7 D014408 $2 czmesh
- 650 _7
- $a prognóza $7 D011379 $2 czmesh
- 650 _7
- $a imunohistochemie $x metody $7 D007150 $2 czmesh
- 650 _7
- $a diagnostické techniky molekulární $x metody $7 D025202 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 _7
- $a ženské pohlaví $7 D005260 $2 czmesh
- 655 _2
- $a časopisecké články $7 D016428
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 700 1_
- $a Kolář, Zdeněk, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $d 1953- $7 jn20000710256
- 700 1_
- $a Ehrmann, Jiří, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $d 1967- $7 jo2003163162
- 700 1_
- $a Kořínková, Gabriela $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $7 xx0087788
- 700 1_
- $a Trojanec, Radek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $7 xx0074936
- 773 0_
- $w MED00193499 $t Oncology letters $x 1792-1074 $g Roč. 13, č. 6 (2017), s. 4201-4207
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28599421 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220315 $b ABA008
- 991 __
- $a 20230110084534 $b ABA008
- 999 __
- $a kom $b bmc $g 1770179 $s 1159333
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 13 $c 6 $d 4201-4207 $e 20170406 $i 1792-1074 $m Oncology letters $n Oncol Lett $x MED00193499
- GRA __
- $a NV16-31997A $p MZ0
- LZP __
- $c NLK120 $d 20230110 $a 2021-granty